RELAPSE
Clinical trials for RELAPSE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE trials appear
Sign up with your email to follow new studies for RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy aims to tame hard-to-treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new treatment for people with Hodgkin lymphoma whose cancer has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The goal is to find a safe dos…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two drugs, epcoritamab and loncastuximab tesirine, is safe and effective for people with large B-cell lymphoma that has come back or stopped responding to treatment. About 26 adults will receive the drug combination, and researchers will monitor…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated May 26, 2026 02:20 UTC
-
Engineered immune cells take on tough breast cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for triple-negative breast cancer that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is …
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 02:09 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis study tests a new treatment for pancreatic cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side effects. About 27 adults will …
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Talking your way to sobriety: new study tests Post-Detox support
Disease control Recruiting nowThis study looks at whether having motivational conversations every two weeks for four months after leaving the hospital can help people with alcohol use disorder stay sober longer. About 104 adults who completed alcohol withdrawal in the hospital will be split into two groups: o…
Matched conditions: RELAPSE
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Engineered immune cells take on returning head and neck cancer
Disease control Recruiting nowThis study is for people with head and neck cancer that has returned after standard treatments. It tests a new therapy where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. The main goals are to see if the treatment is safe and to f…
Matched conditions: RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New cocktail aims to tame returning bone marrow cancer
Disease control Recruiting nowThis study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: Andrew Yee, MD • Aim: Disease control
Last updated May 18, 2026 12:13 UTC